A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
Summary
- Eligibility
- for people ages 18-80 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
- ID
- NCT03524092
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated